** Shares of drugmaker Axsome Therapeutics AXSM.O rise 5.9% to $108.98 premarket
** Company reports Q2 revenue of $150 mln, higher than analysts' estimate of $138.8 mln, according to data compiled by LSEG
** Says sales of its depression drug Auvelity were $119.6 mln in Q2, up 84% from $65 mln a year ago
** Reports Q2 net loss per share of 97 cents, less than loss of $1.67 per share a year earlier
** Up to last close, stock up 21.8% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。